21st European Meeting on Hypertension and Cardiovascular Prevention 2011 - Post-Conference Review and Analysis

21st European Meeting on Hypertension and Cardiovascular Prevention 2011 - Post-Conference Review and Analysis

Summary

GlobalData, the industry analysis specialist, has released its new conference alerts, “21st European Meeting on Hypertension and Cardiovascular Prevention 2011 - Post-Conference Review and Analysis”. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.

21st European Meeting on Hypertension and Cardiovascular Prevention 2011 was held in Milan, between June 17–20, 2011, organized by the European Society of Hypertension. The four day conference included a demonstration of improvements in both treatment options for hypertension and understanding of the mechanisms behind the disease. This report, entitled “21st European Meeting on Hypertension and Cardiovascular Prevention 2011: Post-Conference Review and Analysis”, aims to cover the scientific presentations and articles released during the course of the conference.

Scope

The report provides complete coverage of conference. Its scope includes -
- Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
- Review of pre- and post-conference KOL/analyst comments.
- Market revenue data for 2010 and forecast forward to 2017 for a specific disease area (if the conference being covered is focused on a specific disease area).
- Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.

Reasons to buy

The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
- Explore M&A opportunities by identifying key products and market players.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the market opportunities. SHOW LESS READ MORE >

1 Table of contents
Summary
Key Takeaways
1 Table of contents
1.1 List of Tables
2 21st European Meeting on Hypertension and Cardiovascular Prevention 2011 - Post-Conference Highlights
2.1 Safety and Efficacy of Aliskiren (ALI) in Children - An Eight-day, Multiple-Dose, Open-Label Study
Overview:
Methodology:
Results:
Key Insights:
2.2 Effect of Products of Xanthine-Xanthine Oxidase to Ca++ Dependent Potassium Permeability of Erythrocyte Membranes Patients with Arterial Hypertension Accompanied by Type 2 Diabetes Mellitus
Overview:
Methodology:
Results:
Key Insights:
2.3 Melatonin, Free Radical Activity and Conventional Treatment in Hypertension
Overview:
Methodology:
Results:
Key Insights:
2.4 C-Type Natriuretic Peptide Effects on Vascular Reactivity in Hypertension Participation of Nitric Oxide System
Overview:
Methodology:
Results:
Key Insights:
2.5 The Renin Inhibitor VTP-27999 Blocks Stored Renin More Potently than Aliskiren(ALI)
Overview:
Methodology:
Results:
Key Insights:
2.6 Renin-Angiotensin-Aldosterone-System (RAAS) in Patients with Abdominal Obesity and Hypertension
Overview:
Methodology:
Results:
Key Insights:
2.7 Aliskiren (ALI) Restores Nitric Oxide Availability in the Forearm Microcirculation of Essential Hypertensive (EH) Patients
Overview:
Methodology:
Results:
Key Insights:
2.8 Cardiotrophin-1 is a New Key Player in Cardiac and Vascular Fibrosis and in Cardiovascular Dysfunction beyond Hypertension
Overview:
Methodology:
Results:
Key Insights:
2.9 Clinical Efficacy of the First Renin Inhibitor – Aliskiren (ALI) in Patients with Hypertension and Metabolic Syndrome
Overview:
Methodology:
Results:
Key Insights:
2.10 Hypertension and Renal Functional Toxicity During Vascular Endothelial Growth Factor (VEGF) Receptor Inhibition with Sunitini - Focus on Endothelin-1 and Oxidative Stress
Overview:
Methodology:
Results:
Key Insights:
2.11 Long-Term Cardiovascular Safety of Crystalline Glucosamine Sulfate - A Retrospective Analysis of Two Randomized Controlled Trials
Overview:
Methodology:
Results:
Key Insights:
2.12 Irbesartan/Amlodipine Fixed Combination in Patients Uncontrolled On Amlodipine 5Mg (I-Combine Study)
Overview:
Methodology:
Results:
Conclusion:
2.13 Antihypertensive and Vasoprotective Efficacy of Combined Therapy with Lercanidipine and Perindopril in Hypertensive Patients
Overview:
Methodology:
Results:
Conclusion:
2.14 Efficacy and Safety of Azilsartan Medoxomil/Chlorthalidone with Olmesartan/Hydrochlorothiazide Combinations in Stage II Systolic Hypertension
Overview:
Methodology:
Results:
Conclusion:
2.15 Combined Effects of Calcium Channel Blocker and Angiotensin II Receptor Antagonist in Hypertensive Patients with Type 2 Diabetes
Overview:
Methodology:
Result:
Conclusion:
2.16 The Effect of Different Nitrates forms on 24-Hour Blood Pressure in Patients with Angina Pectoris and Hypertension
Overview:
Methodology:
Results:
Conclusion:
2.17 High Levels of E-Selectin are Associated with a Reduction of SIRT1 Expression in Lymphomonocytes from Subjects with Metabolic Syndrome
Overview:
Methodology:
Results:
Conclusion:
2.18 Effects of Beta-Blockers on Peroxide Oxidation in Ischemic Model of Congestive Heart Failure (CHF) in Rats
Overview:
Methodology:
Results:
Conclusion:
2.19 Abbreviations
HMC-1: Human Mast Cells
HP and HTN: Hypertension
HR: Heart Rate
MAU: Microalbuminuria
2.20 Disclaimer

1.1 List of Tables
Table 1: Mean Change in Blood Pressure from Baseline to End of Treatment by Dose and Age Group
Table 2: Maximal Relaxation (Rmax) and Concentration of the CNP (expressed as negative log molar) Poducing 50% of Maximum Relaxation (pEC50)
Table 3: AZL-M/CLD FDCs Reduced Office and Ambulatory SBP Significantly More Than OLM/HCTZ in this Titration-to-Target Study